AstraZeneca's blocked M&A signals tough CEO finale
BMY•Context on recent share moves
AstraZeneca’s shares fell on August 3, following reports the previous day that the UK-listed pharma group had held merger talks with U.S. peer Bristol Myers Squibb.
Breakingsviews column on AstraZeneca's deal prospects
The former sector leader trades at a discount to Novartis and Roche, amid growth fears. Pascal Soriot, whose 14-year tenure already counts one turnaround, ran into opposition to a union with $137 bln Bristol Myers Squibb. That leaves smaller deals, where competition is fierce.
